140 documents

Read All
01:04 , Jun 11, 2019 |  BC Extra  |  Company News

Why Brii Bio partnered with microbiome start-up Artizan

In its latest move to bring innovation to infectious diseases in China, Brii Bio has partnered with microbiome start-up Artizan, which is approaching IBD as if it were an infectious disease. Artizan Biosciences Inc. (New...
Read More
23:57 , Apr 18, 2019 |  BC Extra  |  Preclinical News

Pig brain tech could spur stroke therapies, drug and target validation

While Wednesday's announcement that Yale researchers restored cell function in postmortem pig brains sheds no light on the feasibility of reviving consciousness, it does suggest new opportunities for stroke treatments, disease models and validation of...
Read More
18:17 , Mar 7, 2019 |  BC Innovations  |  Distillery Therapeutics

Blocking tumor-associated macrophage SIGLEC15 for solid tumors

DISEASE CATEGORY: Cancer INDICATION: Colorectal; melanoma; brain cancer; solid tumors Patient sample, cell culture and mouse studies suggest inhibiting SIGLEC15 expressed on tumor-associated macrophages could help treat colorectal cancer, melanoma, glioblastoma and other solid tumors....
Read More
23:01 , Mar 4, 2019 |  BC Extra  |  Preclinical News

NextCure's macrophage-based alternative to T cell checkpoint inhibitors

A study led by NextCure co-founder and PD-1 pioneer Lieping Chen has found that blocking SIGLEC15 could boost antitumor T cell responses in immunosuppressive tumor microenvironments. NextCure Inc. (Beltsville, Md.) is testing anti-SIGLEC15 mAb NC318...
Read More
17:05 , Aug 23, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers A three-protein signature in tumor-infiltrating lymphocytes (TILs) could help predict response to PD-1 and PD-L1 inhibitors in NSCLC. In pre-treatment tumor samples from 39 NSCLC patients treated with PD-1 or PD-L1 inhibitors,...
Read More
23:05 , Aug 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

New Therapeutic Targets and Biomarkers: July 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2018. Therapeutic targets are defined as any protein, gene or other...
Read More
19:05 , Jul 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Malaria Mouse studies suggest an RNA-based vaccine encoding Plasmodium MIF could help prevent malaria infection. The vaccine consists of a lipid nanoparticle (LNP) loaded with Plasmodium MIF encoded by an alphaviral RNA replicon. In...
Read More
00:33 , Apr 6, 2018 |  BC Innovations  |  Targets & Mechanisms

GI Band-Aid

A trio of Science papers shows a leaky gut can drive systemic inflammation and autoimmunity by allowing bacteria and their products to escape the GI lumen and enter the bloodstream. The results open a variety...
Read More
18:17 , Mar 30, 2018 |  BC Week In Review  |  Company News

JNJ's Janssen increased R&D spending, decreased list prices in 2017

The Janssen Pharmaceuticals unit of Johnson & Johnson (NYSE:JNJ) said it increased R&D spending and lowered annual rate changes of average list price and net price of drugs in 2017 vs. 2016. Data were published...
Read More
15:47 , Mar 28, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Circulating plasmablast and B cell numbers could help predict the risk of high-grade, immune-related adverse events in melanoma patients treated with anti-CTLA-4/anti-PD-1 antibody combinations. In peripheral blood mononuclear cells (PBMCs) from 23...
Read More